Rerouting the GPS Directing Immunotherapy in Endometrial Cancer

Mismatch repair (MMR) status alone is insufficient to guide the use of PD-(L)1 monotherapy in patients with endometrial cancer. Additional biomarkers, including tumor mutational burden and combined positive score, may help to identify patients with MMR-proficient tumors with a high probability of be...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2023-11, Vol.29 (22), p.4521-4523
Hauptverfasser:	Jangra, Rhea, Dhani, Neesha C
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarkers, Tumor Colorectal Neoplasms - pathology DNA Mismatch Repair Endometrial Neoplasms - drug therapy Endometrial Neoplasms - genetics Female Humans Immunotherapy Neoplastic Syndromes, Hereditary - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Mismatch repair (MMR) status alone is insufficient to guide the use of PD-(L)1 monotherapy in patients with endometrial cancer. Additional biomarkers, including tumor mutational burden and combined positive score, may help to identify patients with MMR-proficient tumors with a high probability of benefit from PD-(L)1 monotherapy, and those with MMR-deficient tumors who might require combination strategies. See related article by Oaknin et al., p. 4564.
ISSN:	1078-0432 1557-3265
DOI:	10.1158/1078-0432.CCR-23-1953